EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Achiko AG's enterprise value is CHF0.00 Mil.
Achiko AG's EBITDA for the trailing twelve months (TTM) ended in Jun. 2022 was CHF-5.39 Mil. Therefore, Achiko AG's EV-to-EBITDA for today is 0.00.
The historical rank and industry rank for Achiko AG's EV-to-EBITDA or its related term are showing as below:
XSWX:ACHI's EV-to-EBITDA is not ranked *
in the Healthcare Providers & Services industry.
Industry Median: 12.84 * Ranked among companies with meaningful EV-to-EBITDA only.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2024-06-09), Achiko AG's stock price is CHF0.0004.
Achiko AG's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2022 was CHF-0.049. Therefore, Achiko AG's PE Ratio for today is At Loss.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
Achiko AG EV-to-EBITDA Historical Data
The historical data trend for Achiko AG's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Achiko AG's EV-to-EBITDA
For the Health Information Services subindustry, Achiko AG's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Achiko AG's EV-to-EBITDA Distribution in the Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Achiko AG's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Achiko AG's EV-to-EBITDA falls into.
Achiko AG EV-to-EBITDA Calculation
Achiko AG's EV-to-EBITDA for today is calculated as:
Achiko AG's current Enterprise Value is CHF0.00 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Achiko AG's EBITDA for the trailing twelve months (TTM) ended in Jun. 2022 was CHF-5.39 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Achiko AG (XSWX:ACHI) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Achiko AG's share price for today is CHF0.0004.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Achiko AG's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2022 was CHF-0.049.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of Achiko AG's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Achiko AG is developing disruptive diagnostic solutions that put people first. The company product is a rapid, reliable Covid-19 test with a companion app offering a user-friendly digital health passport. Achiko creates and develops aptamer-based diagnostics through its biotechnology division, AptameX, and companion health apps via its digital mobile health technology division, Teman Sehat. The AptameX DNA aptamer tests can be rapidly chemically synthesized, are cost-effective, and have wide potential across multiple disease diagnostics. Leveraging AptameX and Teman Sehat, Achiko aims to deliver fast, accurate, and affordable diagnostic testing for a range of pathogenic diseases and therapeutic indications in the rapidly evolving healthcare diagnostics field.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
XSWX:ACHI has been successfully added to your